subscribeSubscribe
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO

Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO
BUSINESSWIRE
21 Sep 2023
Share Share
Innate Present Data From PII TELLOMAK Trial Demonstrating Activity of Lacutamab

Innate Present Data From PII TELLOMAK Trial Demonstrating Activity of Lacutamab
BUSINESSWIRE
10 Dec 2022
Share Share
Kyowa Kirin`s Mogamulizumab Receives Supplemental Approval in the U.S.

Kyowa Kirin`s Mogamulizumab Receives Supplemental Approval in the U.S.
FDA
30 Mar 2022
Share Share
NICE recommends mogamulizumab for treatment of ultra-rare blood cancers

NICE recommends mogamulizumab for treatment of ultra-rare blood cancers
PHARMAFILE
11 Nov 2021
Share Share
Kyowa Kirin: New Real World Evidence Underlines Benefits of POTELIGEO for CTCL

Kyowa Kirin: New Real World Evidence Underlines Benefits of POTELIGEO for CTCL
BUSINESSWIRE
14 Oct 2021
Share Share
NICE to reassess Kyowa Kirin’s Poteligeo

NICE to reassess Kyowa Kirin’s Poteligeo
Lucy Parsons PHARMATIMES
15 Jun 2021
Share Share
NICE will revisit appraisal of Kyowa Kirin`s POTELIGEO

NICE will revisit appraisal of Kyowa Kirin`s POTELIGEO
BUSINESSWIRE
11 Jun 2021
Share Share
NICE will revisit appraisal of Kyowa Kirin`s POTELIGEO

NICE will revisit appraisal of Kyowa Kirin`s POTELIGEO
BUSINESSWIRE
11 Jun 2021
Share Share
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response

Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response
BUSINESSWIRE
10 Jun 2021
Share Share
NICE rejects NHS funding for Kyowa Kirin`s Poteligeo

NICE rejects NHS funding for Kyowa Kirin`s Poteligeo
Selina McKee PHARMA TIMES
30 Jul 2020
Share Share